Can direct to consumer access help Vanda scale NEREUS beyond niche travel use?
Motion sickness finally has a new prescription drug. Vanda’s test is whether NEREUS can move beyond travel novelty into real demand.
Could Vanda’s success with NEREUS revive interest in neurokinin-1 pathways?
NEREUS becomes first FDA-approved motion sickness drug in 40 years. Find out how this approval could reshape antiemetic strategies across industries.